On October 29, 2024 Adcendo ApS ("Adcendo"), a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, reported that its CEO, Michael Pehl will join fellow antibody-drug-conjugate (ADC) industry leaders and experts on a panel discussion at the 30th Annual BIO-Europe conference, held in Stockholm, Sweden, from 4th-6th November 2024 (Press release, ADCendo, OCT 29, 2024, View Source [SID1234647529]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The panel discussion at this year’s BIO-Europe event will explore the rapidly expanding ADC sector and provide insights into the current landscape. Panellists will share perspectives on the latest innovations and challenges facing ADC development, as well as the future of ADCs and their potential to reshape the paradigm of precision medicine.
Panel discussion details:
Panel Title: "Two for the Price of One!" The ADC arena
Speaker: Michael Pehl, CEO of Adcendo
Panel Date and Time: Tuesday 5 November, 2024, 14:00 CET
Venue: Stockholmsmässan, Mässvägen 1, 125 30 Älvsjö, Stockholm, Sweden
Location: Room K2
2024 has been a transformative year for Adcendo as the Company shortly transitions into becoming a clinical-stage biotech with two first-in-class programs, ADCE-T02, targeting Tissue Factor (TF) in multiple epithelial cancers, and ADCE-D01, targeting uPARAP in patients with metastatic and/or unresectable STS, entering the clinical stage of development. A Clinical Trial Notification has been submitted for ADCE-T02 in Australia with FPI planned in Q4 2024, and Adcendo has recently received US FDA IND clearance to commence a first-in-human Phase I/II study (ADCElerate-01 Trial) of ADCE-D01.